688180 君实生物
已收盘 02-27 15:00:01
资讯
新帖
简况
iza-bren公告III期结果;君实生物等药企发布业绩快报 | 健讯Daily
21世纪经济报道 · 08:06
iza-bren公告III期结果;君实生物等药企发布业绩快报 | 健讯Daily
君实生物(688180)披露2025年度业绩快报公告,2月27日股价上涨0.18%
证券之星 · 02-27 22:34
君实生物(688180)披露2025年度业绩快报公告,2月27日股价上涨0.18%
科创50指数样本调整:调出君实生物(688180.SH)等三只股份 3月13日盘后生效
智通财经 · 02-27 17:12
科创50指数样本调整:调出君实生物(688180.SH)等三只股份 3月13日盘后生效
君实生物业绩快报:2025年净利润亏损8.74亿元 同比减亏
人民财讯 · 02-27 16:45
君实生物业绩快报:2025年净利润亏损8.74亿元 同比减亏
君实生物与德琪医药达成合作;联影医疗等披露业绩预告
21世纪经济报道 · 02-26 08:05
君实生物与德琪医药达成合作;联影医疗等披露业绩预告
君实生物(688180)披露截至2026年1月31日证券变动月报表,2月25日股价上涨1.4%
证券之星 · 02-25 22:25
君实生物(688180)披露截至2026年1月31日证券变动月报表,2月25日股价上涨1.4%
港股异动 | 德琪医药-B(06996)涨超6% 与君实生物达成临床合作 推进ATG-037与JS207的联合探索
智通财经 · 02-25
港股异动 | 德琪医药-B(06996)涨超6% 与君实生物达成临床合作 推进ATG-037与JS207的联合探索
君实生物与德琪医药达成战略合作,共同开展JS207(PD-1/VEGF双抗)与ATG-037(CD73口服小分子抑制剂)联合用药研究
美通社 · 02-25
君实生物与德琪医药达成战略合作,共同开展JS207(PD-1/VEGF双抗)与ATG-037(CD73口服小分子抑制剂)联合用药研究
君实生物等在河北成立医药公司
人民财讯 · 02-14
君实生物等在河北成立医药公司
君实生物跌1.93% 2020年上市2募资共86亿元
中金财经 · 02-11
君实生物跌1.93% 2020年上市2募资共86亿元
君实生物(01877)获董事长熊俊累计增持10万股
智通财经 · 02-10
君实生物(01877)获董事长熊俊累计增持10万股
君实生物董事长增持10万股A股,累计斥资380万元
美股速递 · 02-10
君实生物董事长增持10万股A股,累计斥资380万元
港股异动 | 君实生物(01877)涨超5% 预期2025年度归母净亏损同比收窄31.85%左右
智通财经 · 02-09
港股异动 | 君实生物(01877)涨超5% 预期2025年度归母净亏损同比收窄31.85%左右
君实生物(688180)披露截至2026年1月31日证券变动月报,2月4日股价上涨0.45%
证券之星 · 02-04
君实生物(688180)披露截至2026年1月31日证券变动月报,2月4日股价上涨0.45%
破发股君实生物连亏10年 2020年上市2募资共86亿元
中金财经 · 02-03
破发股君实生物连亏10年 2020年上市2募资共86亿元
每周股票复盘:君实生物(688180)预计2025年亏损收窄至8.73亿
证券之星 · 02-01
每周股票复盘:君实生物(688180)预计2025年亏损收窄至8.73亿
君实生物(01877)发盈警 预期2025年归母净亏损为8.73亿左右 同比亏损减少 31.85%左右
智通财经 · 01-30
君实生物(01877)发盈警 预期2025年归母净亏损为8.73亿左右 同比亏损减少 31.85%左右
君实生物跌6.02% 连亏9年3季2020年上市2募资共86亿
中金财经 · 01-29
君实生物跌6.02% 连亏9年3季2020年上市2募资共86亿
1月27日君实生物涨7.96%,中信建投医改混合A基金重仓该股
证券之星 · 01-27
1月27日君实生物涨7.96%,中信建投医改混合A基金重仓该股
君实生物涨7.96%,太平洋二个月前给出“买入”评级,目标价51.16元
证券之星 · 01-27
君实生物涨7.96%,太平洋二个月前给出“买入”评级,目标价51.16元
加载更多
公司概况
公司名称:
上海君实生物医药科技股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-15
主营业务:
上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。
发行价格:
55.50
{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":34,"timestamp":1772175601000,"preClose":33.94,"halted":0,"volume":6280787,"delay":0,"changeRate":0.0018,"floatShares":766000000,"shares":1027000000,"eps":-0.9252,"marketStatus":"已收盘","change":0.06,"latestTime":"02-27 15:00:01","open":33.6,"high":34.12,"low":33.55,"amount":213000000,"amplitude":0.0168,"askPrice":34,"askSize":185,"bidPrice":33.98,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-0.9252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":33.94,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":37.33,"lowLimit":30.55,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1026689871,"isCdr":false,"pbRate":5.62,"roa":"--","roe":"--","epsLYR":-1.3,"committee":-0.629358,"marketValue":34907000000,"turnoverRate":0.0082,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-03-02。","afterMarket":{"amount":0,"volume":0,"close":34,"buyVolume":0,"sellVolume":1000,"time":1772177637558,"indexStatus":"已收盘 02-27 15:30:00","preClose":33.94},"hkstockBrief":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":20.48,"timestamp":1772179700004,"preClose":20.22,"halted":0,"volume":1826788,"delay":0,"premium":"-47.14"},"floatMarketCap":26057000000},"requestUrl":"/m/hq/s/688180","defaultTab":"news","newsList":[{"id":"2614289542","title":"iza-bren公告III期结果;君实生物等药企发布业绩快报 | 健讯Daily","url":"https://stock-news.laohu8.com/highlight/detail?id=2614289542","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614289542?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:06","pubTimestamp":1772237206,"startTime":"0","endTime":"0","summary":"国家药监局:2025年共收到创新医疗器械特别审批申请457项近日,国家药监局发布2025年度创新医疗器械等产品注册审批情况。2025年,国家药监局按照《创新医疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作,共收到创新医疗器械特别审批申请457项,其中104项获准进入创新医疗器械特别审查程序;收到优先申请38项,其中26项获准优先审批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657320729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657320729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1515","III","688180","BK4134","01877","BK0239","BK1583"],"gpt_icon":0},{"id":"2614085232","title":"君实生物(688180)披露2025年度业绩快报公告,2月27日股价上涨0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085232","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614085232?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:34","pubTimestamp":1772202857,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,君实生物报收于34.0元,较前一交易日上涨0.18%,最新总市值为349.07亿元。该股当日开盘33.6元,最高34.12元,最低33.55元,成交额达2.13亿元,换手率为0.82%。近日,上海君实生物医药科技股份有限公司发布2025年度业绩快报,营业总收入249,842.03万元,同比增长28.23%;归属于母公司所有者的净利润为-87,438.94万元,亏损较上年同期缩窄。扣除股份支付影响后,净利润亏损同比减少37.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0239","BK1161","BK1515","01877","688180"],"gpt_icon":0},{"id":"2614383305","title":"科创50指数样本调整:调出君实生物(688180.SH)等三只股份 3月13日盘后生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2614383305","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614383305?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:12","pubTimestamp":1772183578,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,根据指数规则,上海证券交易所与中证指数有限公司决定调整科创50等指数样本,于2026年3月13日收市后生效。其中科创50指数更换3只样本,将君实生物(688180.SH)、萤石网络(688475.SH)、天能股份(688819.SH)调出名单;将国盾量子(688027.SH)、中科飞测(688361.SH)、中科星图(688568.SH)调入名单。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688180","BK1515","159371","BK1583","BK0239","BK1161","01877"],"gpt_icon":0},{"id":"2614838715","title":"君实生物业绩快报:2025年净利润亏损8.74亿元 同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614838715","media":"人民财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614838715?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:45","pubTimestamp":1772181902,"startTime":"0","endTime":"0","summary":"【君实生物业绩快报:2025年净利润亏损8.74亿元 同比减亏】君实生物(688180)2月27日发布业绩快报,2025年实现营业总收入24.98亿元,同比增长28.23%;归母净利润亏损8.74亿元,上年同期亏损12.81亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656706343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01877","688180"],"gpt_icon":0},{"id":"2614063998","title":"君实生物与德琪医药达成合作;联影医疗等披露业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2614063998","media":"21世纪经济报道","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614063998?lang=zh_cn&edition=full","pubTime":"2026-02-26 08:05","pubTimestamp":1772064306,"startTime":"0","endTime":"0","summary":"政策动向2026年山东省群众身边不正之风和腐败问题集中整治动员部署会召开山东省医保局官微显示,2月25日上午,2026年全省群众身边不正之风和腐败问题集中整治动员部署会在济南召开,总结工作,分析形势,部署任务,动员全省上下全力打好集中整治攻坚决战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263654683437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263654683437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK0239","688180","BK0251","BK1574","01877","BK1161","688271","BK1515","06996","BK1191"],"gpt_icon":0},{"id":"2614033113","title":"君实生物(688180)披露截至2026年1月31日证券变动月报表,2月25日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614033113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614033113?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:25","pubTimestamp":1772029518,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,君实生物报收于34.75元,较前一交易日上涨1.4%,最新总市值为356.77亿元。近日,君实生物发布H股公告,披露截至2026年1月31日的证券变动月报表。公告显示,公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于港交所上市,A股于上交所科创板上市。股份期权计划方面,H股及A股股票期权激励计划已于2025年9月29日获股东大会批准,本月无新增行权或股份变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","161027","BK1161","BK0239","01877","BK1515","688180"],"gpt_icon":0},{"id":"2614777227","title":"港股异动 | 德琪医药-B(06996)涨超6% 与君实生物达成临床合作 推进ATG-037与JS207的联合探索","url":"https://stock-news.laohu8.com/highlight/detail?id=2614777227","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614777227?lang=zh_cn&edition=full","pubTime":"2026-02-25 14:16","pubTimestamp":1772000181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,德琪医药-B涨超6%,截至发稿,涨6.4%,报3.66港元,成交额1332.6万港元。消息面上,德琪医药今早宣布,公司已与君实生物达成临床合作协议,双方将共同探索德琪医药的ATG-037与君实生物的JS207在中国大陆肿瘤患者中的联合治疗协同潜力。公司指,在免疫检查点抑制剂耐药已成为临床巨大挑战的背景下,ATG-037在I期试验中同CPI联用已展现出了强劲的逆转耐药能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","BK1574","BK1583","VT","688180","06996","BK1515","BK4585","BK4588","BK1191","VXUS","BK1161","BK0239"],"gpt_icon":0},{"id":"2614773959","title":"君实生物与德琪医药达成战略合作,共同开展JS207(PD-1/VEGF双抗)与ATG-037(CD73口服小分子抑制剂)联合用药研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2614773959","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614773959?lang=zh_cn&edition=full","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":"上海2026年2月25日 /美通社/ -- 北京时间2026年2月25日,君实生物宣布与德琪医药达成战略合作,双方将共同探索君实生物自主研发的JS207与德琪医药的ATG-037在中国大陆肿瘤患者中的联合治疗协同潜力。本次合作的科学依据在于CD73抑制与PD-1/VEGF双靶向机制之间的互补性及潜在协同作用。综合上述因素,将CD73阻断与PD-1/VEGF靶向策略联合应用,有望增强并维持治疗效果。JS207可同时以高亲和力结合于PD-1与VEGFA,有效阻断PD-1与PD-L1和PD-L2的结合,并抑制VEGF与其受体的结合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4888412_ZH88412_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1574","BK4023","06996","BK1191","BK1161","BK0239","PD","01877","BK1515","688180","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2611825118","title":"君实生物等在河北成立医药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2611825118","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611825118?lang=zh_cn&edition=full","pubTime":"2026-02-14 11:52","pubTimestamp":1771041155,"startTime":"0","endTime":"0","summary":"人民财讯2月14日电,企查查APP显示,近日,君华(河北)医药有限公司成立,法定代表人为童景,注册资本为2000万元,经营范围包含:生物基材料制造;生物化工产品技术研发;药品生产;药品批发;药品委托生产等。企查查股权穿透显示,该公司由君实生物旗下上海君拓生物医药科技有限公司等共同持股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602143650964879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK0239","BK1161","688180","BK1515","01877"],"gpt_icon":0},{"id":"2610982090","title":"君实生物跌1.93% 2020年上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610982090","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610982090?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:49","pubTimestamp":1770799778,"startTime":"0","endTime":"0","summary":"中国经济网北京2月11日讯 君实生物 今日收报35.03元,跌幅1.93%。 上市首日,君实生物股价最高报220.40元,为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元,扣除发行费用后,募集资金净额为44.97亿元,较原计划多17.97亿元。 君实生物首次公开发行股票发行费用为3.39亿元,其中,保荐及承销费用3.20亿元。 经计算,君实生物两次募集资金合计86.12亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260211/32012393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688180","BK1161","BK1583","BK1515","01877","BK0239"],"gpt_icon":0},{"id":"2610633641","title":"君实生物(01877)获董事长熊俊累计增持10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633641","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610633641?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:25","pubTimestamp":1770722741,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物(01877)公布控股股东、实际控制人之一兼董事长增持股份进展,截至本公告披露日,熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司 A 股股份10万股,约占公司总股本的 0.01%,累计成交总额为人民币 383.84 万元。本次增持计划尚未实施完毕,熊俊先生将继续按照相关增持计划,在增持计划实施期间内择机增持公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403806.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","688180","BK0239","BK1583","BK1161","01877"],"gpt_icon":0},{"id":"1178068811","title":"君实生物董事长增持10万股A股,累计斥资380万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1178068811","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178068811?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:19","pubTimestamp":1770722354,"startTime":"0","endTime":"0","summary":"截至2月10日,君实生物董事长通过二级市场增持公司A股股份10万股,合计交易金额达380万元人民币。此次增持体现了公司管理层对未来发展前景的信心,并向市场传递积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0239","01877","BK1161","BK1515","688180"],"gpt_icon":0},{"id":"2610186504","title":"港股异动 | 君实生物(01877)涨超5% 预期2025年度归母净亏损同比收窄31.85%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2610186504","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610186504?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:12","pubTimestamp":1770603152,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,君实生物涨超5%,截至发稿,涨4.81%,报21.8港元,成交额3991.48万港元。消息面上,近日,君实生物发布公告,预计2025年年度实现营业收入25亿元左右,同比增长28.32%左右。预计2025年年度实现归属于母公司所有者的净亏损为8.73亿左右,同比亏损减少31.85%左右。报告期内,公司营业收入增长,主要系商业化药品的销售收入与上年同期相比有所增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","688180","BK4585","VT","01877","BK1583","BK1515","VXUS","BK1161","BK0239"],"gpt_icon":0},{"id":"2608360500","title":"君实生物(688180)披露截至2026年1月31日证券变动月报,2月4日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360500","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360500?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:10","pubTimestamp":1770214233,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,君实生物报收于35.41元,较前一交易日上涨0.45%,最新总市值为363.55亿元。近日,君实生物发布《截至2026年1月31日的证券变动月报》。公告显示,截至2026年1月31日,公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。H股于港交所上市,A股于上交所科创板上市。股份期权计划方面,H股及A股股票期权激励计划于2025年9月29日获批准采纳,本月内无新增行权或股份变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","161027","01877","BK1515","BK0239","688180","BK1583"],"gpt_icon":0},{"id":"2608848840","title":"破发股君实生物连亏10年 2020年上市2募资共86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848840","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608848840?lang=zh_cn&edition=full","pubTime":"2026-02-03 10:44","pubTimestamp":1770086649,"startTime":"0","endTime":"0","summary":"中国经济网北京2月3日讯 君实生物 近日发布的2025年年度业绩预告显示,经财务部门初步测算,预计2025年年度实现营业收入250,000.00万元左右,与上年同期相比增长55,168.27万元左右,同比增长28.32%左右。 上市首日,君实生物股价最高报220.40元,为上市以来股价最高点。 君实生物首次公开发行股票发行费用为3.39亿元,其中,保荐及承销费用3.20亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260203/31993921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1583","BK1515","01877","BK1161","688180","BK0239"],"gpt_icon":0},{"id":"2608778300","title":"每周股票复盘:君实生物(688180)预计2025年亏损收窄至8.73亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608778300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608778300?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:16","pubTimestamp":1769883373,"startTime":"0","endTime":"0","summary":"业绩披露要点君实生物发布业绩预告,预计2025年全年归属净利润亏损约8.73亿元,亏损同比减少31.85%。公司公告汇总上海君实生物医药科技股份有限公司2026年度第一期科技创新债券已成功发行,募集资金于2026年1月26日到账。本期债券名称为上海君实生物医药科技股份有限公司2026年度第一期科技创新债券,简称26君实生物MTN001(科创债),代码102680280,期限3+2年,起息日为2026年1月26日,兑付日为2031年1月26日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","01877","BK1583","BK0239","688180","BK1515"],"gpt_icon":0},{"id":"2607801466","title":"君实生物(01877)发盈警 预期2025年归母净亏损为8.73亿左右 同比亏损减少 31.85%左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2607801466","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607801466?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:08","pubTimestamp":1769771285,"startTime":"0","endTime":"0","summary":"智通财经APP讯,君实生物 公布,预计 2025 年年度实现营业收入25亿元左右,同比增长 28.32%左右。预计 2025 年年度实现归属于母公司所有者的净亏损为8.73亿左右,同比亏损减少 31.85%左右。报告期内,公司营业收入增长,主要系商业化药品的销售收入与上年同期相比有所增长。其中,JS207 目前已处于 II 期临床研究阶段,正在多个瘤种中开展与化疗、单抗、ADC 等不同药物的联合探索,JS207 与 JS212 联合用药的 II 期临床试验正在进行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1515","BK1583","688180","BK1161","01877"],"gpt_icon":0},{"id":"2607702637","title":"君实生物跌6.02% 连亏9年3季2020年上市2募资共86亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2607702637","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607702637?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:03","pubTimestamp":1769677399,"startTime":"0","endTime":"0","summary":"中国经济网北京1月29日讯 君实生物 今日收报36.82元,跌幅6.02%。该股目前处于破发状态。 上市首日,君实生物股价最高报220.40元,为上市以来股价最高点。 君实生物首次公开发行股票募集资金总额为48.36亿元,扣除发行费用后,募集资金净额为44.97亿元,较原计划多17.97亿元。 君实生物首次公开发行股票募的发行费用为3.39亿元,其中,保荐及承销费用3.20亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260129/31983200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1583","BK1515","BK0239","688180","BK1161","01877"],"gpt_icon":0},{"id":"2606201471","title":"1月27日君实生物涨7.96%,中信建投医改混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201471?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:35","pubTimestamp":1769502907,"startTime":"0","endTime":"0","summary":"证券之星消息,1月27日君实生物涨7.96%创60日新高,收盘报40.98元,换手率6.7%,成交量51.32万手,成交额20.23亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共22家,其中持有数量最多的公募基金为中信建投基金的中信建投医改混合A。中信建投医改混合A目前规模为4.75亿元,最新净值1.8143,较上一交易日下跌1.14%,近一年上涨24.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700026997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","601066","BK1583","01877","BK0239","BK0276","688180","BK1161"],"gpt_icon":0},{"id":"2606014782","title":"君实生物涨7.96%,太平洋二个月前给出“买入”评级,目标价51.16元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606014782","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606014782?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:34","pubTimestamp":1769502893,"startTime":"0","endTime":"0","summary":"今日君实生物涨7.96%,收盘报40.98元。2025年10月30日,太平洋研究员周豫,戎晓婕发布了对君实生物的研报《拓益收入同比增长40%,持续关注PD-1/VEGF数据读出》,该研报对君实生物给出“买入”评级,认为其目标价为51.16元,现价距离目标价尚有24.84%的涨幅空间。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为71.63%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为中信证券的韩世通。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700026990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01877","601099","688180"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772277455095,"stockEarnings":[{"period":"1week","weight":-0.0079},{"period":"1month","weight":-0.1322},{"period":"3month","weight":-0.0836},{"period":"6month","weight":-0.2443},{"period":"1year","weight":0.0642},{"period":"ytd","weight":-0.0047}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35877人(较上一季度增加15.17%)","perCapita":"21361股","listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路987号4层","registeredCapital":"102668万元","survey":" 上海君实生物医药科技股份有限公司的主营业务是创新药物的发现和开发、在全球范围内的临床研究、大规模生产到商业化的全产业链。公司的主要产品是以源头创新、自主研发类生物制品为主,同时通过合作开发、设立合资企业以及许可(license-in)等形式引进与自有源创产品线有协同作用的药物或平台技术,进一步壮大产品管线。曾荣膺国家专利领域最高奖项“中国专利金奖”,并获得“十二五”、“十三五”两项“重大新药创制”国家重大科技专项支持。","listedPrice":55.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}